{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T09:00:12Z","timestamp":1772269212114,"version":"3.50.1"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T00:00:00Z","timestamp":1659657600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cardiovasc Disord"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Sarcopenia is prevalent in heart failure (HF) patients, contributing to its poor prognosis. Statin use is postulated as a probable risk for developing sarcopenia, but little is known regarding this association in HF patients. This work aims at classifying and characterising sarcopenia and at describing the association of statin use with sarcopenia in a sample of Portuguese HF outpatients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In this cross-sectional study, a sample of 136 HF patients (median age: 59\u00a0years, 33.8% women) was recruited from an HF outpatients\u2019 clinic of a University Hospital in Portugal. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People 2. Clinical, nutritional, and dietary data were collected.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 25 (18.4%) individuals were categorised as sarcopenic, ranging from 12.2% in younger (&lt;\u200965\u00a0years) participants vs. 30.4% in older ones and from 3.3% in men vs. 47.8% in women. Severe sarcopenia accounted for 7.4% of the sample and sarcopenic obesity was identified in 5.1% of the individuals. A total of 65.4% of the participants were statin users. In multivariable analysis (n\u2009=\u2009132, 25 sarcopenic), the use of statins was inversely associated with sarcopenia (OR\u2009=\u20090.03; 95% CI\u2009=\u20090.01, 0.30). Each additional age year was associated with a 9% increase in the likelihood of being sarcopenic (OR\u2009=\u20091.09; 95% CI\u2009=\u20091.01, 1.17), and each Kg.m<jats:sup>\u22122<\/jats:sup> increment in body mass index was associated with a 21% decrease in the likelihood of sarcopenia (OR\u2009=\u20090.79; 95% CI\u2009=\u20090.65, 0.96). The daily use of five or more medicines was also directly associated with sarcopenia (OR\u2009=\u200926.87; 95% CI\u2009=\u20092.01, 359.26). On the other hand, being a man and being physically active were inversely associated with sarcopenia (OR\u2009=\u20090.01; 95% CI\u2009=\u20090.00, 0.07 and OR\u2009=\u20090.09; 95% CI\u2009=\u20090.01, 0.65, respectively).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Contrary to what was expected, patients medicated with statins were less likely to be sarcopenic. Although this finding deserves further research, we hypothesise that this might be related to the pleiotropic effects of statins on endothelial function, contributing to better neuromuscular fitness.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12872-022-02804-5","type":"journal-article","created":{"date-parts":[[2022,8,5]],"date-time":"2022-08-05T08:16:54Z","timestamp":1659687414000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Statins are associated with reduced likelihood of sarcopenia in a sample of heart failure outpatients: a cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Rui","family":"Valdiviesso","sequence":"first","affiliation":[]},{"given":"Ana Rita","family":"Sousa-Santos","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds F.","family":"Azevedo","sequence":"additional","affiliation":[]},{"given":"Em\u00edlia","family":"Moreira","sequence":"additional","affiliation":[]},{"given":"Teresa F.","family":"Amaral","sequence":"additional","affiliation":[]},{"given":"Jos\u00e9","family":"Silva-Cardoso","sequence":"additional","affiliation":[]},{"given":"Nuno","family":"Borges","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2022,8,5]]},"reference":[{"issue":"1","key":"2804_CR1","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1093\/ageing\/afy169","volume":"48","author":"AJ Cruz-Jentoft","year":"2019","unstructured":"Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruy\u00e8re O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019;48(1):16\u201331.","journal-title":"Age Ageing"},{"issue":"4","key":"2804_CR2","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1017\/S0029665115002438","volume":"74","author":"S von Haehling","year":"2015","unstructured":"von Haehling S. The wasting continuum in heart failure: from sarcopenia to cachexia. Proc Nutr Soc. 2015;74(4):367\u201377.","journal-title":"Proc Nutr Soc"},{"issue":"1","key":"2804_CR3","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3390\/nu12010211","volume":"12","author":"F Curcio","year":"2020","unstructured":"Curcio F, Testa G, Liguori I, Papillo M, Flocco V, Panicara V, et al. Sarcopenia and heart failure. Nutrients. 2020;12(1):211.","journal-title":"Nutrients"},{"issue":"9","key":"2804_CR4","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1093\/eurjpc\/zwaa117","volume":"28","author":"M Konishi","year":"2021","unstructured":"Konishi M, Kagiyama N, Kamiya K, Saito H, Saito K, Ogasahara Y, et al. Impact of sarcopenia on prognosis in patients with heart failure with reduced and preserved ejection fraction. Eur J Prev Cardiol. 2021;28(9):1022\u20139. https:\/\/doi.org\/10.1093\/eurjpc\/zwaa117.","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"2804_CR5","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1002\/ehf2.13255","volume":"8","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang J, Ni W, Yuan X, Zhang H, Li P, et al. Sarcopenia in heart failure: a systematic review and meta-analysis. ESC Heart Fail. 2021;8(2):1007\u201317.","journal-title":"ESC Heart Fail"},{"issue":"1\u20132","key":"2804_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000448247","volume":"99","author":"L Campins","year":"2017","unstructured":"Campins L, Camps M, Riera A, Pleguezuelos E, Yebenes JC, Serra-Prat M. Oral drugs related with muscle wasting and sarcopenia: a review. Pharmacology. 2017;99(1\u20132):1\u20138.","journal-title":"Pharmacology"},{"issue":"Suppl 3","key":"2804_CR7","first-page":"32","volume":"26","author":"JM McKenney","year":"2007","unstructured":"McKenney JM. Pharmacologic characteristics of statins. Clin Cardiol. 2007;26(Suppl 3):32\u20138.","journal-title":"Clin Cardiol"},{"issue":"4","key":"2804_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.tips.2018.02.003","volume":"39","author":"A Bielecka-Dabrowa","year":"2018","unstructured":"Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, et al. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci. 2018;39(4):331\u201353.","journal-title":"Trends Pharmacol Sci"},{"issue":"18","key":"2804_CR9","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1186\/s12944-019-1135-z","volume":"31","author":"A Bielecka-Dabrowa","year":"2019","unstructured":"Bielecka-Dabrowa A, Byty\u00e7i I, Von Haehling S, Anker S, Jozwiak J, Rysz J, et al. Association of statin use and clinical outcomes in heart failure patients: a systematic review and meta-analysis. Lipids Health Dis. 2019;31(18):188.","journal-title":"Lipids Health Dis"},{"issue":"36","key":"2804_CR10","doi-asserted-by":"publisher","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","volume":"42","author":"TA McDonagh","year":"2021","unstructured":"McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, B\u00f6hm M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: Developed by the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) With the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2021;42(36):3599\u2013726.","journal-title":"Eur Heart J"},{"issue":"10","key":"2804_CR11","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s11883-019-0800-z","volume":"21","author":"MMY Lee","year":"2019","unstructured":"Lee MMY, Sattar N, McMurray JJV, Packard CJ. Statins in the prevention and treatment of heart failure: a review of the evidence. Curr Atheroscler Rep. 2019;21(10):41.","journal-title":"Curr Atheroscler Rep"},{"issue":"10","key":"2804_CR12","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11910-020-01064-0","volume":"20","author":"E Crisan","year":"2020","unstructured":"Crisan E, Patil VK. Neuromuscular complications of statin therapy. Curr Neurol Neurosci Rep. 2020;20(10):47.","journal-title":"Curr Neurol Neurosci Rep"},{"issue":"3","key":"2804_CR13","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1016\/j.jacl.2019.04.011","volume":"13","author":"TA Jacobson","year":"2019","unstructured":"Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, L\u00f3pez JAG, et al. The STatin Adverse Treatment Experience Survey: experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415\u201324.","journal-title":"J Clin Lipidol"},{"issue":"6","key":"2804_CR14","doi-asserted-by":"publisher","first-page":"1217","DOI":"10.21037\/cdt-21-312","volume":"11","author":"J Cabral","year":"2021","unstructured":"Cabral J, Vasconcelos H, Maia-Ara\u00fajo P, Moreira E, Campelo M, Amorim S, et al. Sacubitril\/valsartan in everyday clinical practice: an observational study based on the experience of a heart failure clinic. Cardiovasc Diagn Ther. 2021;11(6):1217\u201327.","journal-title":"Cardiovasc Diagn Ther"},{"issue":"8","key":"2804_CR15","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1016\/j.numecd.2021.03.028","volume":"31","author":"R Valdiviesso","year":"2021","unstructured":"Valdiviesso R, Azevedo LF, Moreira E, Ata\u00edde R, Martins S, Fernandes L, et al. Frailty phenotype and associated nutritional factors in a sample of Portuguese outpatients with heart failure. Nutr Metab Cardiovasc Dis NMCD. 2021;31(8):2391\u20137.","journal-title":"Nutr Metab Cardiovasc Dis NMCD"},{"key":"2804_CR16","first-page":"271","volume":"53","author":"DB Jelliffe","year":"1966","unstructured":"Jelliffe DB. The assessment of the nutritional status of the community (with special reference to field surveys in developing regions of the world). World Health Organ. 1966;53:271.","journal-title":"World Health Organ"},{"key":"2804_CR17","unstructured":"Schectman O, Sindhu B. Grip Strenght. In: Clinical Assessment Recommendations. American Society of Hand Therapists; 2015."},{"issue":"12","key":"2804_CR18","doi-asserted-by":"publisher","first-page":"e113637","DOI":"10.1371\/journal.pone.0113637","volume":"9","author":"RM Dodds","year":"2014","unstructured":"Dodds RM, Syddall HE, Cooper R, Benzeval M, Deary IJ, Dennison EM, et al. Grip strength across the life course: normative data from twelve british studies. PLoS ONE. 2014;9(12):e113637.","journal-title":"PLoS ONE"},{"issue":"3","key":"2804_CR19","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.clnu.2013.07.013","volume":"33","author":"F Landi","year":"2014","unstructured":"Landi F, Onder G, Russo A, Liperoti R, Tosato M, Martone AM, et al. Calf circumference, frailty and physical performance among older adults living in the community. Clin Nutr Edinb Scotl. 2014;33(3):539\u201344.","journal-title":"Clin Nutr Edinb Scotl"},{"issue":"5","key":"2804_CR20","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.clnu.2012.02.007","volume":"31","author":"F Landi","year":"2012","unstructured":"Landi F, Liperoti R, Russo A, Giovannini S, Tosato M, Capoluongo E, et al. Sarcopenia as a risk factor for falls in elderly individuals: results from the ilSIRENTE study. Clin Nutr. 2012;31(5):652\u20138.","journal-title":"Clin Nutr"},{"issue":"6","key":"2804_CR21","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1097\/MCO.0b013e328312c37d","volume":"11","author":"S Stenholm","year":"2008","unstructured":"Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Sarcopenic obesity\u2014definition, etiology and consequences. Curr Opin Clin Nutr Metab Care. 2008;11(6):693\u2013700.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"key":"2804_CR22","unstructured":"The Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, Mass.: Little, Brown & Co; 1994. pp. 253\u2013256"},{"key":"2804_CR23","doi-asserted-by":"crossref","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE. What is polypharmacy? A systematic review of definitions. BMC Geriatr. 2017;17. Available from: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5635569\/","DOI":"10.1186\/s12877-017-0621-2"},{"issue":"8","key":"2804_CR24","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.1249\/01.MSS.0000078924.61453.FB","volume":"35","author":"CL Craig","year":"2003","unstructured":"Craig CL, Marshall AL, Sj\u00f6str\u00f6m M, Bauman AE, Booth ML, Ainsworth BE, et al. International physical activity questionnaire: 12-country reliability and validity. Med Sci Sports Exerc. 2003;35(8):1381\u201395.","journal-title":"Med Sci Sports Exerc"},{"key":"2804_CR25","unstructured":"International Physical Activity Questionnaire. Secondary Guidelines for Data Processing and Analysis of the International Physical Activity Questionnaire (IPAQ)\u2014Short Form. [Internet]. 2004. Available from: http:\/\/www.institutferran.org\/documentos\/scoring_short_ipaq_april04.pdf."},{"key":"2804_CR26","first-page":"50","volume-title":"Nutritional epidemiology","author":"M Buzzard","year":"1998","unstructured":"Buzzard M. 24-hours dietary recall and food record methods. In: Nutritional epidemiology. 2nd ed. Oxford: Oxford University Press; 1998. p. 50\u201373.","edition":"2"},{"key":"2804_CR27","volume-title":"Manual de quantifica\u00e7\u00e3o de alimentos","author":"M Marques","year":"1996","unstructured":"Marques M, de Almeida MDV, Pinho O. Manual de quantifica\u00e7\u00e3o de alimentos. Porto: Faculdade de Ci\u00eancias da Nutri\u00e7\u00e3o e Alimenta\u00e7\u00e3o da Universidade do Porto; 1996."},{"key":"2804_CR28","volume-title":"Pesos e por\u00e7\u00f5es de alimentos","author":"A Goios","year":"2016","unstructured":"Goios A, Liz Martins M, Oliveira AC, Afonso C, Amaral T. Pesos e por\u00e7\u00f5es de alimentos. Porto: Universidade do Porto; 2016."},{"key":"2804_CR29","unstructured":"Tabela da Composi\u00e7\u00e3o de Alimentos [Internet]. Instituto Nacional de Sa\u00fade Dr. Ricardo Jorge, I. P.\u2014INSA; 2006. Available from: http:\/\/portfir.insa.pt"},{"key":"2804_CR30","volume-title":"Sample Size Calculations in Clinical Research. CRC Biostatistics Series","author":"S Chow","year":"2008","unstructured":"Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research. CRC Biostatistics Series. 2nd ed. New York: Chapman & Hall; 2008.","edition":"2"},{"key":"2804_CR31","unstructured":"Test Odds Ratio Equality | Power and Sample Size Calculators | HyLown [Internet]. [cited 2022 Apr 13]. Available from: http:\/\/powerandsamplesize.com\/Calculators\/Test-Odds-Ratio\/Equality"},{"issue":"5","key":"2804_CR32","first-page":"604","volume":"76","author":"AR Sousa-Santos","year":"2019","unstructured":"Sousa-Santos AR, Afonso C, Borges N, Santos A, Padr\u00e3o P, Moreira P, et al. Factors associated with sarcopenia and undernutrition in older adults. Nutr Diet J Dietit Assoc Aust. 2019;76(5):604\u201312.","journal-title":"Nutr Diet J Dietit Assoc Aust"},{"issue":"4","key":"2804_CR33","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1016\/S0008-6363(00)00146-2","volume":"47","author":"KK Koh","year":"2000","unstructured":"Koh KK. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res. 2000;47(4):648\u201357.","journal-title":"Cardiovasc Res"},{"issue":"12","key":"2804_CR34","doi-asserted-by":"publisher","first-page":"2051","DOI":"10.3390\/jcm8122051","volume":"8","author":"AM Gorabi","year":"2019","unstructured":"Gorabi AM, Kiaie N, Hajighasemi S, Banach M, Penson PE, Jamialahmadi T, et al. Statin-induced nitric oxide signaling: mechanisms and therapeutic implications. J Clin Med. 2019;8(12):2051.","journal-title":"J Clin Med"},{"key":"2804_CR35","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ejim.2019.10.008","volume":"71","author":"M Correale","year":"2020","unstructured":"Correale M, Paolillo S, Mercurio V, Limongelli G, Barill\u00e0 F, Ruocco G, et al. Comorbidities in chronic heart failure: an update from Italian Society of Cardiology (SIC) Working Group on Heart Failure. Eur J Intern Med. 2020;71:23\u201331.","journal-title":"Eur J Intern Med"},{"issue":"3","key":"2804_CR36","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.jamda.2016.09.006","volume":"18","author":"MR Dos Santos","year":"2017","unstructured":"Dos Santos MR, Saitoh M, Ebner N, Valentova M, Konishi M, Ishida J, et al. Sarcopenia and endothelial function in patients with chronic heart failure: results from the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). J Am Med Dir Assoc. 2017;18(3):240\u20135.","journal-title":"J Am Med Dir Assoc"},{"issue":"6","key":"2804_CR37","doi-asserted-by":"publisher","first-page":"1034","DOI":"10.1002\/jcsm.12340","volume":"9","author":"J Yoo","year":"2018","unstructured":"Yoo J, Kim M, Na J, Chun Y, Park Y, Park Y, et al. Relationship between endothelial function and skeletal muscle strength in community dwelling elderly women. J Cachexia Sarcopenia Muscle. 2018;9(6):1034\u201341.","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"3","key":"2804_CR38","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1093\/ageing\/afaa237","volume":"50","author":"AT Amarasekera","year":"2021","unstructured":"Amarasekera AT, Chang D, Schwarz P, Tan TC. Does vascular endothelial dysfunction play a role in physical frailty and sarcopenia? A systematic review. Age Ageing. 2021;50(3):725\u201332.","journal-title":"Age Ageing"},{"issue":"37","key":"2804_CR39","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.1016\/j.clnu.2018.06.1342","volume":"1","author":"A Molfino","year":"2018","unstructured":"Molfino A, Lai S, Amabile MI, Mitterhofer AP, Muscaritoli M. Sarcopenia and markers of atherosclerosis and endothelial dysfunction: preliminary results from an Italian cohort of CKD patients. Clin Nutr. 2018;1(37):S87.","journal-title":"Clin Nutr"},{"issue":"12","key":"2804_CR40","doi-asserted-by":"publisher","first-page":"11200","DOI":"10.18632\/aging.103450","volume":"12","author":"E Alcalde-Est\u00e9vez","year":"2020","unstructured":"Alcalde-Est\u00e9vez E, Asenjo-Bueno A, Sosa P, Olmos G, Plaza P, Caballero-Mora M\u00c1, et al. Endothelin-1 induces cellular senescence and fibrosis in cultured myoblasts. A potential mechanism of aging-related sarcopenia. Aging. 2020;12(12):11200\u201323.","journal-title":"Aging"},{"issue":"2","key":"2804_CR41","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.atherosclerosis.2015.05.022","volume":"241","author":"A Sahebkar","year":"2015","unstructured":"Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241(2):433\u201342.","journal-title":"Atherosclerosis"},{"issue":"1","key":"2804_CR42","doi-asserted-by":"publisher","first-page":"57","DOI":"10.15420\/cfr.2018.31.1","volume":"5","author":"JH Morris","year":"2019","unstructured":"Morris JH, Chen L. Exercise training and heart failure: a review of the literature. Card Fail Rev. 2019;5(1):57\u201361.","journal-title":"Card Fail Rev"},{"issue":"6","key":"2804_CR43","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1007\/s12603-019-1196-8","volume":"23","author":"D Beckw\u00e9e","year":"2019","unstructured":"Beckw\u00e9e D, Delaere A, Aelbrecht S, Baert V, Beaudart C, Bruyere O, et al. Exercise interventions for the prevention and treatment of sarcopenia. A systematic umbrella review. J Nutr Health Aging. 2019;23(6):494\u2013502.","journal-title":"J Nutr Health Aging."},{"issue":"8","key":"2804_CR44","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1016\/j.jchf.2016.05.006","volume":"4","author":"JP Kelly","year":"2016","unstructured":"Kelly JP, Dunning A, Schulte PJ, Fiuzat M, Leifer ES, Fleg JL, et al. Statins and exercise training response in heart failure patients: insights from HF-ACTION. JACC Heart Fail. 2016;4(8):617\u201324.","journal-title":"JACC Heart Fail"},{"issue":"7","key":"2804_CR45","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1001\/jamainternmed.2014.1927","volume":"174","author":"T Sugiyama","year":"2014","unstructured":"Sugiyama T, Tsugawa Y, Tseng CH, Kobayashi Y, Shapiro MF. Different time trends of caloric and fat intake between statin users and nonusers among US adults: gluttony in the time of statins? JAMA Intern Med. 2014;174(7):1038\u201345.","journal-title":"JAMA Intern Med"},{"issue":"6","key":"2804_CR46","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1177\/2047487316684054","volume":"24","author":"S Johal","year":"2017","unstructured":"Johal S, Jamsen KM, Bell JS, Mc Namara KP, Magliano DJ, Liew D, et al. Do statin users adhere to a healthy diet and lifestyle? The Australian Diabetes, Obesity and Lifestyle Study. Eur J Prev Cardiol. 2017;24(6):621\u20137.","journal-title":"Eur J Prev Cardiol"},{"key":"2804_CR47","first-page":"1","volume":"2","author":"J Beezer","year":"2021","unstructured":"Beezer J, Al Hatrushi M, HusbandSlovaki A, Kurdi A, Forsyth P. Polypharmacy definition and prevalence in heart failure: a systematic review. Heart Fail Rev. 2021;2:1\u201328.","journal-title":"Heart Fail Rev"},{"issue":"4","key":"2804_CR48","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.hfc.2014.07.005","volume":"10","author":"BN Reed","year":"2014","unstructured":"Reed BN, Rodgers JE, Sueta CA. Polypharmacy in heart failure: drugs to use and avoid. Heart Fail Clin. 2014;10(4):577\u201390.","journal-title":"Heart Fail Clin"},{"issue":"3","key":"2804_CR49","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1001\/jama.292.3.344","volume":"292","author":"VL Roger","year":"2004","unstructured":"Roger VL, Weston SA, Redfield MM, Hellermann-Homan JP, Killian J, Yawn BP, et al. Trends in heart failure incidence and survival in a community-based population. JAMA. 2004;292(3):344\u201350.","journal-title":"JAMA"},{"issue":"16","key":"2804_CR50","doi-asserted-by":"publisher","first-page":"e147","DOI":"10.1016\/j.jacc.2013.05.019","volume":"62","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, et al. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013;62(16):e147-239.","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"2804_CR51","doi-asserted-by":"publisher","first-page":"1865","DOI":"10.1007\/s11606-019-05106-3","volume":"34","author":"A Katsimpris","year":"2019","unstructured":"Katsimpris A, Linseisen J, Meisinger C, Volaklis K. The association between polypharmacy and physical function in older adults: a systematic review. J Gen Intern Med. 2019;34(9):1865\u201373.","journal-title":"J Gen Intern Med"},{"issue":"1","key":"2804_CR52","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/gerona\/glx074","volume":"73","author":"M K\u00f6nig","year":"2018","unstructured":"K\u00f6nig M, Spira D, Demuth I, Steinhagen-Thiessen E, Norman K. Polypharmacy as a risk factor for clinically relevant sarcopenia: results from the berlin aging study II. J Gerontol Ser A. 2018;73(1):117\u201322.","journal-title":"J Gerontol Ser A"},{"issue":"Suppl 1","key":"2804_CR53","first-page":"988","volume":"2","author":"T Tanaka","year":"2018","unstructured":"Tanaka T, Akishita M, Unyaporn S, Iijima K. Polypharmacy as a predictor of sarcopenia, disability, and mortality among community-dwelling older adults. Innov Aging. 2018;2(Suppl 1):988.","journal-title":"Innov Aging"},{"key":"2804_CR54","doi-asserted-by":"publisher","first-page":"110801","DOI":"10.1016\/j.exger.2019.110801","volume":"131","author":"J Pacifico","year":"2020","unstructured":"Pacifico J, Geerlings MAJ, Reijnierse EM, Phassouliotis C, Lim WK, Maier AB. Prevalence of sarcopenia as a comorbid disease: a systematic review and meta-analysis. Exp Gerontol. 2020;131:110801.","journal-title":"Exp Gerontol"},{"issue":"6","key":"2804_CR55","doi-asserted-by":"publisher","first-page":"616","DOI":"10.1016\/j.nut.2011.10.006","volume":"28","author":"A Casas-Vara","year":"2012","unstructured":"Casas-Vara A, Santolaria F, Fern\u00e1ndez-Bereciart\u00faa A, Gonz\u00e1lez-Reimers E, Garc\u00eda-Ochoa A, Mart\u00ednez-Riera A. The obesity paradox in elderly patients with heart failure: analysis of nutritional status. Nutr Burbank Los Angel Cty Calif. 2012;28(6):616\u201322.","journal-title":"Nutr Burbank Los Angel Cty Calif"},{"issue":"5","key":"2804_CR56","first-page":"434","volume":"101","author":"P Zuchinali","year":"2013","unstructured":"Zuchinali P, Souza GC, Alves FD, d\u2019Almeida KSM, Goldraich LA, Clausell NO, et al. Triceps skinfold as a prognostic predictor in outpatient heart failure. Arq Bras Cardiol. 2013;101(5):434\u201341.","journal-title":"Arq Bras Cardiol"},{"issue":"97","key":"2804_CR57","doi-asserted-by":"publisher","first-page":"104517","DOI":"10.1016\/j.archger.2021.104517","volume":"1","author":"AR Sousa-Santos","year":"2021","unstructured":"Sousa-Santos AR, Barros D, Montanha TL, Carvalho J, Amaral TF. Which is the best alternative to estimate muscle mass for sarcopenia diagnosis when DXA is unavailable? Arch Gerontol Geriatr. 2021;1(97):104517.","journal-title":"Arch Gerontol Geriatr"},{"issue":"8","key":"2804_CR58","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.annepidem.2009.04.010","volume":"19","author":"Y Ma","year":"2009","unstructured":"Ma Y, Olendzki BC, Pagoto SL, Hurley TG, Magner RP, Ockene IS, et al. Number of 24-hour diet recalls needed to estimate energy intake. Ann Epidemiol. 2009;19(8):553\u20139.","journal-title":"Ann Epidemiol"},{"issue":"1","key":"2804_CR59","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1161\/CIRCHEARTFAILURE.110.957480","volume":"4","author":"DS Lee","year":"2011","unstructured":"Lee DS, Gona P, Albano I, Larson MG, Benjamin EJ, Levy D, et al. A systematic assessment of causes of death after heart failure onset in the community: impact of age at death, time period, and left ventricular systolic dysfunction. Circ Heart Fail. 2011;4(1):36\u201343.","journal-title":"Circ Heart Fail"}],"container-title":["BMC Cardiovascular Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12872-022-02804-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12872-022-02804-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,15]],"date-time":"2022-08-15T10:35:53Z","timestamp":1660559753000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccardiovascdisord.biomedcentral.com\/articles\/10.1186\/s12872-022-02804-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,5]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2804"],"URL":"https:\/\/doi.org\/10.1186\/s12872-022-02804-5","relation":{},"ISSN":["1471-2261"],"issn-type":[{"value":"1471-2261","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,5]]},"assertion":[{"value":"15 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This work abides by the Declaration of Helsinki. All participants gave their informed consent to the anonymous use of data for research purposes. The study protocol was reviewed and approved by the Ethics Committee of the Hospital Centre where the study was conducted (reference 57\/17 of the Ethics Committee of the <i>Centro Hospitalar Universit\u00e1rio de S\u00e3o Jo\u00e3o<\/i>).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"356"}}